Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1681903

	registered interest
	date	15/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of medicinal cannabis treatments provided by the NHS; and whether she has plans to increase the number of treatments available.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	9453
	answer	answer is ministerial correction date of answer 17/01/2024 answer text <p>Licensed cannabis-based medicines are available and funded on the National Health Service, where the safety, quality and clinical and cost effectiveness has been assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence.</p><p>The Government continues to encourage manufacturers to develop new treatments and invest in research and clinical trials, and offers scientific and research advice from the MHRA and the National Institute for Health and Care Research.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/01/2024 17:12:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1447 label Biography information for Andrew Rosindell

1682606

	registered interest
	date	16/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the potential merits of allowing children to be issued medical cannabis prescriptions on the NHS.
	tabling member constituency	Somerton and Frome
	tabling member printed	Sarah Dyke
	uin	9974
	answer	answer is ministerial correction date of answer 22/01/2024 answer text <p>Licensed cannabis-based medicines, that have been proved effective in clinical trials and judged cost-effective by the National Institute of Health and Care Excellence (NICE), are routinely available on the National Health Service, including for people aged over two years old with certain types of epilepsy. However, clinical guidelines from NICE demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/01/2024 14:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4995 label Biography information for Sarah Dyke

1687065

	registered interest
	date	02/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress she has made with (a) regulatory, (b) research and (c) NHS partners on establishing clinical trials to test the (i) safety and (ii) efficacy of medical cannabis products.
	tabling member constituency	Somerton and Frome
	tabling member printed	Sarah Dyke
	uin	12872
	answer	answer is ministerial correction date of answer 09/02/2024 answer text <p>The Department, via the National Institute for Health and Care Research (NIHR), is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and the results will be published once the trials have completed and the findings peer reviewed.</p><p> </p><p>Furthermore, the Government continues to encourage manufacturers to invest in research and has highlighted that public funding is available for high quality applications. The Medicines and Healthcare products Regulatory Agency and the NIHR can provide applicants with scientific and research advice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 09/02/2024 10:47:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4995 label Biography information for Sarah Dyke

1689392

	registered interest
	date	16/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans her Department has to make medicinal cannabis more accessible to those who need it.
	tabling member constituency	Liverpool, Wavertree
	tabling member printed	Paula Barker
	uin	14291
	answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence (NICE) demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p> </p><p>The Government continues to call on manufacturers to invest in research and clinical trials to prove if their products are safe and effective and offers scientific and research advice from the Medicines and Healthcare products Regulatory Agency and the NICE.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/02/2024 09:43:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4828 label Biography information for Paula Barker

1689862

	registered interest
	date	19/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people aged under 18 have been prescribed medicinal cannabis as of 19 February 2024.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	14583
	answer	answer is ministerial correction date of answer 27/02/2024 answer text <p>The Department does not hold details relating to the age of people prescribed medicinal cannabis.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/02/2024 11:18:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1136423

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have, if any, to extend the availability of medicinal cannabis to people with diseases that cause chronic pain.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16873
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16874 HL16875 question first answered 10/07/2019 15:30:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1136424

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of (1) the advantages, and (2) the disadvantages, of allowing medical professionals to prescribe medicinal cannabis to people suffering from chronic pain.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16874
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16873 HL16875 question first answered 10/07/2019 15:30:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1136425

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what studies (1) have been carried out, and (2) are proposed, to investigate the pain relief impacts of medicinal cannabis on people who have multiple sclerosis.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16875
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16873 HL16874 question first answered 10/07/2019 15:30:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1052543

	registered interest
	date	01/02/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many applications for licences to cultivate cannabis for medicinal purposes in the UK they have received since 1 January 2016.
	tabling member printed	Lord Wasserman
	uin	HL13376
	answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>No licences have been issued to cultivate cannabis for medicinal purposes. Licences are issued to cultivate High THC cannabis for research and/or the extraction of cannabinoids.</p> answering member printed Baroness Williams of Trafford grouped question UIN HL13377 HL13378 question first answered 14/02/2019 17:27:41 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	4207 label Biography information for Lord Wasserman

1052544

	registered interest
	date	01/02/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many licences for the cultivation of cannabis for medicinal purposes they have (1) granted, and (2) refused since 1 January 2016.
	tabling member printed	Lord Wasserman
	uin	HL13377
	answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>No licences have been issued to cultivate cannabis for medicinal purposes. Licences are issued to cultivate High THC cannabis for research and/or the extraction of cannabinoids.</p> answering member printed Baroness Williams of Trafford grouped question UIN HL13376 HL13378 question first answered 14/02/2019 17:27:41 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	4207 label Biography information for Lord Wasserman